Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus Belgique
  • Aires thérapeutiques
  • Ressources
Campus Belgique
  • Aires thérapeutiques
  • Ressources
View Full Results

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.

Explorer

Switching from other basal insulins to Toujeo (Insulin Glargine)

Explorer

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

Explorer

The RESTORE-G Real World Evidence Study

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

Explorer

The observational ORION study

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.

Explorer

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Explorer

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Explorer

Le pouvoir de réduire le chaos lié au VRS

Explorer

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Explorer

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Explorer

Cardiovascular diseases (CVDs) are the leading cause of death globally

Explorer

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Explorer